News|Articles|May 29, 2024

Psychedelics Safety Poll

Key Takeaways

Answer a quick question on psychedelics!

How do you perceive the safety profile of psychedelics compared with traditional psychiatric medications?

Comparable
Current psychopharmacological options are much safer
Current psychopharmacological options are a little safer
Psychedelics are safer

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

View more
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
Multimedia

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

View more
PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia
Video

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

View more
Southern Florida Psychiatry Conference
In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Register now!
Real Psychiatry 2026
In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

View more
Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?
Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

View more
Optimizing Care for Patients With Tardive Dyskinesia
Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

View more
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

View more
(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

View more
(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

View more
(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

View more
(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

View more
Contact Info

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us